

The English text is an unofficial translation. In case of any discrepancies between the Swedish text and the English translation, the Swedish text shall prevail.

Resolution on authorization regarding issues

For the purposes of enabling the board of directors to develop the company's capital structure, diversify the shareholder base, finance or carry out acquisitions or other arrangements, the board of directors of Immunovia AB proposes the annual general meeting on 13 May 2026 to authorize the board of directors to resolve, on one or several occasions before the next annual general meeting, with or without deviation from the shareholders' preferential rights and with or without provisions regarding payment in kind, set-off or other provisions, to issue new shares, convertibles and/or warrants. The total number of shares that may be issued pursuant to the authorization (alternatively be issued through conversion of convertibles and/or exercise of warrants) shall be limited to a number that corresponds to a maximum of 20% of the number of shares outstanding in the company at the time of the first issue resolution pursuant to the authorization. To the extent an issue is made with deviation from the shareholders' preferential rights, the issue shall be made on market terms.

For a valid resolution, the proposal must be supported by shareholders representing at least two-thirds of the votes cast as well as of all shares represented at the general meeting.

The company's CEO shall be authorized to make minor formal adjustments of the resolution which may be required for registration with the Swedish Companies Registration Office (Sw. Bolagsverket).

Lund in April 2026

The Board of Directors of Immunovia AB (publ)